1 January 2021 in Medical Bulletin of Haseki
27 October 2023 in Anatolian Current Medical Journal
Aims: To examine the link between serum anti-mullerian hormone (AMH) levels and homeostatic model assessment of insulin resistance (HOMA-IR) in different phenotypes of polycystic ovary syndrome (PCOS). Methods: This retrospective study included 120 patients aged 18-30 who visited our polyclinics between June 2021 and December 2022. Patients were divided into four groups based on the Rotterdam criteria for PCOS phenotypes. A control group of 24 individuals was also included. Clinical data, hormonal profiles, and metabolic parameters were obtained from medical records. Results: There were significant differences in AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), and high-density lipoprotein (HDL) levels among the PCOS phenotypes and control group. AMH levels were highest in phenotype 1 (oligo/anovulation + hyperandrogenism + polycystic ovaries) and lowest in the control group. FSH were highest in phenotype 4 (oligo/anovulation + polycystic ovaries) and lowest in the control group. LH were highest in phenotype 2 (oligo/anovulation + hyperandrogenism). HOMA-IR was highest in phenotype 1. However, there were no significant differences in AMH or HOMA-IR levels among the PCOS phenotypes. Conclusion: Our study found hormone level differences among PCOS phenotypes but no significant differences in AMH or HOMA-IR. This suggests AMH may not distinguish between phenotypes and insulin resistance may not differ significantly among phenotypes.
1 January 2020 in Medical Bulletin of Haseki
22 October 2022 in Anatolian Current Medical Journal
Aim: Regardless of medical advancements, ectopic pregnancy (EP) is still an essential factor in the mortality rate of women of reproductive age. The main aim of this study was to determine predictive factors associated with the success of the response to treatment with single-dose and two-dose methotrexate (MTX) regimens in women with tubal EP. Material and Method: This retrospective study examined the electronic records of 130 patients who underwent treatment due to EP were included in the study. The patients were divided into two groups: the successful MTX treatment group (n: 85) as the case group and the failure of MTX treatment group (n: 45) as the control group. Results: Age-matched (30.62±4.36) and body mass index (BMI)-matched (24.37±2.29) patients diagnosed with EP were treated with MTX. The mean beta-human chorionic gonadotropin (β-hCG) value on the first day of treatment was 1639.84±524.96 mIU/mL in the successful and 5866.76±1875.51 mIU/mL in the unsuccessful group. 85 of 130 (65%) were successfully treated with MTX. Five of 45 (35%) failed medical treatment and required laparoscopic surgery. The longest ectopic mass diameter was significantly higher in the failure of MTX treatment group (p
20 October 2023 in Journal of Controversies in Obstetrics & Gynecology and Pediatrics
Aims: Hyperprolactinemia (HPRL), a condition characterized by elevated levels of prolactin (PRL) hormone, is considered to be related to various autoimmune diseases, such as thyroid autoimmunity (TAI). The association between HPRL and TAI still evokes controversy. Our study intends to examine the possible relationship between HPL and TAI in young women. Methods: This retrospective study was done between January 2018 and December 2022, including 90 women with HPRL and 90 control subjects of similar age and gender. A retrospective examination was conducted on the medical records of 90 patients with HPRL to gather relevant data. Information regarding related parameters was analyzed and compared to the control group data. Results: Our results found that thyroid stimulating hormone (TSH) levels were notably elevated in patients with HPRL compared to healthy women (2.24 vs. 1.86). Also, a statistically significant association between the case and control regarding serum free triiodothyronine (fT3) (p0.05). Patients with HPRL demonstrated considerably higher anti thyroperoxidase antibody (anti-TPO) levels (46.08 vs. 43.95). Significantly elevated antithyroglobulin antibody (anti-Tg) levels were observed in patients with HPRL (1.07 vs. 0.84). Conclusion: The study suggests a potential link between HPRL and TAI. Further research is needed to explore this relationship and its implications for patient care.
22 December 2025 in Clinical and Experimental Obstetrics & Gynecology
Background: Unexplained infertility (UI) affects a significant portion of couples worldwide, posing challenges for effective treatment. The prognostic nutritional index (PNI), traditionally used in oncology, has been adapted to evaluate reproductive outcomes, particularly in the context of in vitro fertilization (IVF). Method: This study analyzed 198 non-obese couples undergoing IVF for UI at a tertiary care center between February 2023 and December 2024. This study assessed the correlation between the PNI, comprehensive hematological profiles, and IVF outcomes, including embryo quality and pregnancy. The PNI was obtained through serum albumin and lymphocyte counts. Results: The PNI was elevated in the high-quality embryos (51.65 ± 5.09) compared to those of mild-quality (48.10 ± 2.82) and low-quality (44.20 ± 4.16) (p = 0.0001). A higher PNI was associated with improved embryo quality, with an odds ratio of 11.859 (p = 0.0001) for higher quality embryos. Other inflammatory markers did not demonstrate a predictive value for IVF outcomes (p > 0.05). The PNI yielded an area under the curve (AUC) value of 0.895 (95% confidence interval (CI): 0.85–0.94; p = 0.001), indicating robust discrimination. At a cutoff of 46.5, the PNI demonstrated 81.2% sensitivity and 80.1% specificity, further underscoring the potential of this index as a discriminative marker. Conclusions: The PNI serves as a strong indicator of IVF outcomes, correlating directly with embryo quality and the success of fertility treatments. Moreover, the predictive potential of the PNI for embryo quality in reproductive medicine highlights the intersection of nutritional and immunological status with reproductive health, offering a framework for enhancing clinical assessments in IVF.